Caris Life Sciences Says Detect Demand Already Outstripping a Capacity Base It Is Tripling to $3 Billion, While Unveiling a Personalized Cancer Vaccine Pipeline Built on Its Early Detection Data
Q2 2026 earnings call, held August 5, 2026, following results for the quarter ended June 30, 2026
Caris Life Sciences delivered a quarter that management framed as proof its early-2026 sales reorganization is working, raising full-year revenue guidance to $1.03 billion to $1.04 billion from a prior $1.0 billion to $1.02 billion, implying 27% to 28% growth. But the more consequential disclosures came from the pipeline: the company revealed granular clinical performance data for its newly launched multi-cancer early detection test, Caris Detect, and introduced what it calls the "mutational cleanse," an AI-driven pathway from early detection straight into personalized cancer vaccines. Founder, Chairman and CEO David Halbert also disclosed that demand for Detect is running so far ahead of expectations that the company is tripling processing capacity to roughly $3 billion in annual revenue capability and still expects to see backorders.
Detect Demand Is Outrunning a Capacity Base Being Tripled
The single most striking data point on the call was Halbert's disclosure that Caris' current processing capacity for Detect equates to roughly $1 billion of annual revenue, and the company is "just about to triple that" to approximately $3 billion, "and we're still worried about back orders." That is an extraordinary statement about demand for a product that only launched in June, self-pay, with no FDA approval or CMS reimbursement yet in place. CFO Luke Power said the $47 million sequential increase in inventory from the first to second quarter was deliberate, built specifically to get ahead of Detect volume, and that free cash flow is expected to dip to roughly breakeven by the end of the third quarter as the company burns through the cash generated in the first half to fund that ramp before recovering in the fourth quarter. Notably, none of this prospective Detect volume is baked into the raised guidance. Power was explicit that the guidance increase is driven purely by the existing molecular profiling business, telling analysts, "We're not assuming anything for Detect... we don't want to put numbers out there until we have a history of it coming in." A national direct-to-consumer advertising campaign is set to begin filming imminently and will run nationally within a couple of months, layered on top of channel partnerships with concierge medicine, longevity centers and digital platforms such as Everlywell.
The "Mutational Cleanse": Caris' Pivot From Detection to Intervention
President David Spetzler used much of the call to lay out a four-step pipeline Caris is calling the mutational cleanse, which the company positions as the natural extension of Detect rather than a separate program. When Detect flags a cancer signal early, Caris re-interrogates the circulating tumor DNA at 10,000-times depth of coverage using what it calls the MAX assay, layering in HLA and germline logic to separate genuine somatic mutations from noise. Proprietary AI, trained on a dataset that includes thousands of specimens collected before and after immunotherapy administration, then scores each candidate mutation for pathogenicity, clonality, expression, antigen processing, HLA fit and off-target risk to identify which mutations are actually visible to the immune system. Spetzler cited an 83.8% positive predictive value and 86.5% sensitivity on the top variant per patient. The final step converts the top neoepitopes into patient-specific immune targets that can be monitored over time against circulating tumor DNA and T-cell response. Halbert summarized the strategic logic bluntly: "Find the dangerous mutations early and go after them before they do harm. This is the arc from early detection to early interception." Management also indicated the same sequencing-database-AI architecture is intended to eventually extend beyond oncology into cardiology, neurology and autoimmune disease, though those remain conceptual at this stage.
Detect's Diagnostic Workup Data: Fewer Procedures, Faster Answers
Beyond the vaccine narrative, Caris disclosed validation data on Detect's tissue-of-origin classifier that is directly relevant to its commercial pitch to payers and physicians. Across roughly 2,500 true-positive patients, 83.9% were resolved with a single diagnostic workup and 99.8% within two, for an average of 1.19 procedures per patient. Even in the false-positive cohort, essentially 100% were resolved within two workups. Spetzler argued this matters because it converts what is typically an open-ended diagnostic hunt into "a short prioritized workup," reducing radiation exposure and cost while directly addressing metastases of unknown primary, one of oncology's hardest diagnostic categories. The test currently covers 58 cancer types from a single blood draw, spanning solid tumors and hematological malignancies, which Caris positions as differentiated from narrower methylation-based competitors.
Two Parallel MRD Programs, With Reimbursement Timing Still Uncertain
Caris confirmed it will launch into minimal residual disease testing in the second half of 2026 via two distinct assays: a tumor-naive test built on whole exome and whole transcriptome sequencing through the Caris Assure platform, launching first in colorectal cancer for Stage 2 and 3 patients post-treatment, and a tumor-informed whole genome assay under the Caris Precision platform intended for pan-tumor Stage 1 through 3 disease. Spetzler cited strong analytic performance for the tumor-informed approach, including over five logs of linear dynamic range and a median of roughly 15,000 trackers per patient. However, the MolDX submission timeline for the tumor-informed assay remains uncertain. Spetzler said Caris needs "at least" another six months of clinical outcome maturity data before it can submit, adding that the timeline "really depends on the rate of relapse within our patient population, which is, of course, impossible to really predict."
Core Business Reacceleration Drives the Guidance Raise
Total revenue grew 45% year-over-year to $263.7 million, with molecular profiling revenue up 55% to $252.3 million. Clinical case volume hit a record 59,200 cases, up 18% year-over-year and 12% sequentially, with management attributing the reacceleration to a January 2026 sales force realignment that expanded territories from 82 to 146. The commercial team grew from 270 at the end of the first quarter to 290 at the end of the second, and Power disclosed the headcount has already surpassed 300 in July, with further expansion planned. Blended clinical average selling price hit a record $3,850, and management guided to $3,800 to $3,900 in the third quarter. GAAP gross margin expanded to 68% from 63% a year ago, though Power was clear the company has no near-term intention of compressing costs further to boost margin, stating the philosophy remains "deeper, not cheaper" in how assays are developed and run. Adjusted EBITDA rose to $55.7 million from $16.7 million a year ago, and the company posted its fifth consecutive quarter of positive adjusted EBITDA and positive free cash flow, generating $6.4 million in free cash flow despite significant capital expenditure tied to MCED lab capacity.
Balance Sheet Strength Supports a New Buyback
Caris ended the quarter with $793 million in cash and investments, and its board authorized a $100 million share repurchase program, of which roughly $18 million was executed in the open market during the quarter. Management characterized the balance sheet as the source of "unique strategic flexibility" that allows the company to fund Detect and MRD investment internally without external capital. On potential M&A, Power indicated the bar remains high: "We haven't seen anything out there that speaks to our interest just yet," reiterating a preference to build organically because internally developed comprehensive assays are viewed as best-in-class.
Sequencing Supplier Diversification Could Lower Costs
In response to an analyst question, Spetzler disclosed that Caris is now evaluating two additional sequencing suppliers beyond its long-standing partner, characterizing their throughput as significantly higher and their cost significantly lower than what is currently available. He said this creates the opportunity to simultaneously increase capacity and decrease cost of goods sold, a dynamic that could support gross margin expansion in future years even as management insists it is not currently prioritizing margin optimization over assay quality.
Reimbursement Progress Is Real but Incremental
ChromoSeq, the company's heme therapy selection assay, launched April 1 and received its first Medicare reimbursement at $3,228 under MolDX. Covered lives for MI Cancer Seek reached approximately 239.5 million and for Caris Assure approximately 131.9 million, with management pursuing a similar payer-coverage strategy for Assure that it used successfully for its flagship tissue test. MI Clarity's version 2, adding chemotherapy and extended endocrine therapy decision support, does not yet have a dedicated reimbursement code, with Power indicating the company is pursuing both a potential local coverage determination update and direct conversations with commercial payers given the assay's lower cost relative to sequencing-based tests. New York State approval for Caris Assure remains pending and has not been incorporated into guidance, representing a potential incremental catalyst rather than a baked-in assumption.
Where the Guidance Raise Does Not Reach
Investors should note what the raised outlook excludes. Management was unambiguous that the guidance increase reflects only the existing molecular profiling business and does not assume any contribution from Detect, ChromoSeq or MI Clarity, nor any benefit from prior-period reimbursement true-ups, which Power described as "kind of standard now" across the industry rather than a one-time tailwind. Pharma R&D services revenue came in at $11.4 million, below expectations, though Power expects sequential improvement into the third quarter and a fourth-quarter weighting consistent with prior years as the company prioritizes longer-term partnerships over smaller one-time deals. GAAP operating expenses guidance was also raised, to $595 million to $600 million from $590 million to $595 million, reflecting continued commercial expansion and marketing spend behind the new product launches.